Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

VIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN

VIFOR PHARMA
Posted on: 28 Mar 18

 

  • Vifor Pharma gives Zeria exclusive rights to develop and market Veltassa® in Japan
  • Potential of Veltassa® further validated with expansion into Japanese market
  • Deal expands cardio-renal network with Vifor Pharma's trusted Japanese partner for Ferinject®, Zeria Pharmaceuticals Co., Ltd.

 

VIFOR PHARMA GROUP has granted japanese company ZERIA pharmaceutical co., ltd. exclusive rights to develop and commercialise VELTASSA® in japan.

 

Under the terms of the agreement, Zeria will have the exclusive right to develop Veltassa® for the Japanese market and, once marketing authorisation has been granted, to commercialise it in Japan.

 

The collaboration with Zeria represents an important step in Vifor Pharma's promise to make Veltassa® available to patients worldwide. Having Veltassa® and Ferinject® commercialised through the same partner represents a substantive step for Vifor Pharma in its goal towards expanding its cardio-renal network and becoming the global leader in cardio-renal therapies.

 

"We are very pleased about strengthening our partnership with Zeria and having made a significant step towards making Veltassa® available in Japan, the third-largest pharmaceutical market. We feel extremely fortunate that our trusted partner, Zeria, has chosen to further collaborate with us in offering this novel treatment to hyperkalaemia patients, including those on renin angiotensin aldosterone system inhibitor (RAASi) therapy. RAASi patients benefit in particular because Veltassa® enables them to keep receiving an optimal dose of, and therefore the maximum live-saving benefit from, RAASi treatment," said Stefan Schulze, President of the Executive Committee and COO of Vifor Pharma Group.

 

 

FURTHER INFORMATION

 

Media Relations

Investor Relations

 

Victoria Maier

Senior External Communications Manager

Julien Vignot

Head of Investor Relations

 

Tel.: +41 58 851 80 16

Tel.: +41 58 851 66 90

 

E-mail: media@viforpharma.com

E-mail: investors@viforpharma.com

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 28/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.